Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
July 7, 2021

July 7, 2021 - NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors

David Schnell
July 7, 2021

Source:https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-initiation-phase-12-clinical-study-ngm707

Newer PostJuly 22, 2021 - NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Older PostJuly 1, 2021 - NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners